WO2012126178A3 - 用于治疗肝脏疾病的药物组合物 - Google Patents

用于治疗肝脏疾病的药物组合物 Download PDF

Info

Publication number: WO2012126178A3
Authority: WO; WIPO (PCT)
Prior art keywords: pharmaceutical composition; improving; hepatic disease; treating hepatic; beta
Prior art date: 2011-03-22

Application number

PCT/CN2011/072045

Other languages

English (en)

French (fr)

Other versions

WO2012126178A2 (zh

Inventor

张秀凤

马俊贤

杨国义

林士弘

林坚栋

黄凯文

Original Assignee

财团法人工业技术研究院

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-22

Filing date

2011-03-22

Publication date

2012-11-22

2011-03-22 Application filed by 财团法人工业技术研究院 filed Critical 财团法人工业技术研究院

2011-03-22 Priority to CA2830616A priority Critical patent/CA2830616C/en

2011-03-22 Priority to KR1020167033543A priority patent/KR101981378B1/ko

2011-03-22 Priority to KR1020137027665A priority patent/KR20140020966A/ko

2011-03-22 Priority to JP2014500226A priority patent/JP6166251B2/ja

2011-03-22 Priority to ES11861553.3T priority patent/ES2668785T3/es

2011-03-22 Priority to PL11861553T priority patent/PL2689777T3/pl

2011-03-22 Priority to DK11861553.3T priority patent/DK2689777T3/en

2011-03-22 Priority to SG2013069604A priority patent/SG193486A1/en

2011-03-22 Priority to EP11861553.3A priority patent/EP2689777B1/en

2011-03-22 Priority to CN201180069476.5A priority patent/CN103442709B/zh

2011-03-22 Priority to PCT/CN2011/072045 priority patent/WO2012126178A2/zh

2011-03-22 Priority to NO11861553A priority patent/NO2689777T3/no

2011-03-22 Priority to RU2013146602/15A priority patent/RU2561688C2/ru

2011-03-22 Priority to AU2011362905A priority patent/AU2011362905B2/en

2012-09-27 Publication of WO2012126178A2 publication Critical patent/WO2012126178A2/zh

2012-11-22 Publication of WO2012126178A3 publication Critical patent/WO2012126178A3/zh

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 3
208000019423 liver disease Diseases 0.000 title 1
XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 abstract 2
CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 abstract 2
MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 abstract 2
HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 abstract 2
229920002414 procyanidin Polymers 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
208000019425 cirrhosis of liver Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
208000006454 hepatitis Diseases 0.000 abstract 1
231100000283 hepatitis Toxicity 0.000 abstract 1
206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
210000004185 liver Anatomy 0.000 abstract 1
230000003908 liver function Effects 0.000 abstract 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
239000000178 monomer Substances 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Botany (AREA)
Medical Informatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

PCT/CN2011/072045 2011-03-22 2011-03-22 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物 WO2012126178A2 (zh)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
CA2830616A CA2830616C (en)	2011-03-22	2011-03-22	Pharmaceutical composition for treating hepatic disease
KR1020167033543A KR101981378B1 (ko)	2011-03-22	2011-03-22	간 질환 치료용 약학 조성물
KR1020137027665A KR20140020966A (ko)	2011-03-22	2011-03-22	간 질환 치료용 약학 조성물
JP2014500226A JP6166251B2 (ja)	2011-03-22	2011-03-22	障害を受けた肝臓の再生を促進させる医薬組成物
ES11861553.3T ES2668785T3 (es)	2011-03-22	2011-03-22	Composición farmacéutica para inducir la regeneración hepática
PL11861553T PL2689777T3 (pl)	2011-03-22	2011-03-22	Kompozycja farmaceutyczna do pobudzania regeneracji wątroby
DK11861553.3T DK2689777T3 (en)	2011-03-22	2011-03-22	PHARMACEUTICAL COMPOSITION TO INPUT HEPATIC REGENERATION
SG2013069604A SG193486A1 (en)	2011-03-22	2011-03-22	Pharmaceutical composition for treating hepatic disease
EP11861553.3A EP2689777B1 (en)	2011-03-22	2011-03-22	Pharmaceutical composition for inducing hepatic regeneration
CN201180069476.5A CN103442709B (zh)	2011-03-22	2011-03-22	减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物
PCT/CN2011/072045 WO2012126178A2 (zh)	2011-03-22	2011-03-22	减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物
NO11861553A NO2689777T3 (zh)	2011-03-22	2011-03-22
RU2013146602/15A RU2561688C2 (ru)	2011-03-22	2011-03-22	Фармацевтическая композиция для лечения болезни печени
AU2011362905A AU2011362905B2 (en)	2011-03-22	2011-03-22	Pharmaceutical composition for treating hepatic disease

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/CN2011/072045 WO2012126178A2 (zh)	2011-03-22	2011-03-22	减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物

Publications (2)

Publication Number	Publication Date
WO2012126178A2 WO2012126178A2 (zh)	2012-09-27
WO2012126178A3 true WO2012126178A3 (zh)	2012-11-22

Family

ID=46879777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/CN2011/072045 WO2012126178A2 (zh)	2011-03-22	2011-03-22	减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物

Country Status (13)

Country	Link
EP (1)	EP2689777B1 (zh)
JP (1)	JP6166251B2 (zh)
KR (2)	KR20140020966A (zh)
CN (1)	CN103442709B (zh)
AU (1)	AU2011362905B2 (zh)
CA (1)	CA2830616C (zh)
DK (1)	DK2689777T3 (zh)
ES (1)	ES2668785T3 (zh)
NO (1)	NO2689777T3 (zh)
PL (1)	PL2689777T3 (zh)
RU (1)	RU2561688C2 (zh)
SG (1)	SG193486A1 (zh)
WO (1)	WO2012126178A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140179774A1 (en)	2012-12-26	2014-06-26	Industrial Technology Research Institute	Methods for inhibition of shc-1/p66 to combat aging-related diseases
CN104774909A (zh) *	2014-10-17	2015-07-15	江苏大学	一种原花青素诱导肝癌细胞自噬性死亡的分析方法及应用
WO2022080846A1 (ko) *	2020-10-13	2022-04-21	서울대학교병원	플라본을 포함하는 섬유증의 예방 또는 치료용 조성물
WO2022205137A1 (zh) *	2021-03-31	2022-10-06	贝尔克斯生技股份有限公司	高聚原花青素组合物及其应用
CN115010720B (zh) *	2022-06-02	2023-08-11	中国科学院昆明植物研究所	中甸艾中倍半萜二聚体及其药物组合物与其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1443533A (zh) *	2002-03-07	2003-09-24	程彦杰	原花青素类化合物在用于制备解酒保肝产品方面的用途
CN1933818A (zh) *	2004-01-30	2007-03-21	马尔斯公司	用于治疗癌症的方法和组合物
JP2009242374A (ja) *	2008-03-14	2009-10-22	Miyazakiken Sangyo Shien Zaidan	肝線維化抑制剤
CN101822372A (zh) *	2009-03-05	2010-09-08	财团法人工业技术研究院	用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6713506B2 (en) *	2000-10-11	2004-03-30	University Of South Florida	Tea polyphenol esters and analogs thereof for cancer prevention and treatment
TW200505468A (en) *	2003-08-11	2005-02-16	Suntory Ltd	Agent for improving hepato-bililary dysfunction
US20070054868A1 (en) *	2005-06-20	2007-03-08	The Trustees Of Columbia University In The City Of New York	Synergistic polyphenol compounds, compositions thereof, and uses thereof
JP2008156265A (ja) *	2006-12-22	2008-07-10	Yamagata Prefecture	Ａ型プロアントシアニジンオリゴマー画分及びその製造方法
JP2008195672A (ja) *	2007-02-14	2008-08-28	Okayama Univ	経口摂取用組成物及び経口摂取用組成物の製造方法
TWI370736B (en) *	2008-12-31	2012-08-21	Ind Tech Res Inst	Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus
CN101507730B (zh) *	2009-03-26	2011-01-26	复旦大学	表没食子儿茶素没食子酸酯与柔红霉素的组合物及其应用

2011
- 2011-03-22 ES ES11861553.3T patent/ES2668785T3/es active Active
- 2011-03-22 KR KR1020137027665A patent/KR20140020966A/ko not_active Application Discontinuation
- 2011-03-22 RU RU2013146602/15A patent/RU2561688C2/ru active
- 2011-03-22 CA CA2830616A patent/CA2830616C/en active Active
- 2011-03-22 NO NO11861553A patent/NO2689777T3/no unknown
- 2011-03-22 WO PCT/CN2011/072045 patent/WO2012126178A2/zh active Application Filing
- 2011-03-22 KR KR1020167033543A patent/KR101981378B1/ko active IP Right Grant
- 2011-03-22 PL PL11861553T patent/PL2689777T3/pl unknown
- 2011-03-22 JP JP2014500226A patent/JP6166251B2/ja active Active
- 2011-03-22 DK DK11861553.3T patent/DK2689777T3/en active
- 2011-03-22 AU AU2011362905A patent/AU2011362905B2/en active Active
- 2011-03-22 CN CN201180069476.5A patent/CN103442709B/zh active Active
- 2011-03-22 EP EP11861553.3A patent/EP2689777B1/en active Active
- 2011-03-22 SG SG2013069604A patent/SG193486A1/en unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1443533A (zh) *	2002-03-07	2003-09-24	程彦杰	原花青素类化合物在用于制备解酒保肝产品方面的用途
CN1933818A (zh) *	2004-01-30	2007-03-21	马尔斯公司	用于治疗癌症的方法和组合物
JP2009242374A (ja) *	2008-03-14	2009-10-22	Miyazakiken Sangyo Shien Zaidan	肝線維化抑制剤
CN101822372A (zh) *	2009-03-05	2010-09-08	财团法人工业技术研究院	用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品

Also Published As

Publication number	Publication date
WO2012126178A2 (zh)	2012-09-27
SG193486A1 (en)	2013-10-30
AU2011362905A1 (en)	2013-10-31
KR20160143868A (ko)	2016-12-14
JP2014508785A (ja)	2014-04-10
NO2689777T3 (zh)	2018-08-25
RU2561688C2 (ru)	2015-08-27
CN103442709B (zh)	2018-10-19
DK2689777T3 (en)	2018-05-22
EP2689777A4 (en)	2014-09-17
AU2011362905B2 (en)	2015-11-12
CA2830616A1 (en)	2012-09-27
KR20140020966A (ko)	2014-02-19
CA2830616C (en)	2017-02-21
JP6166251B2 (ja)	2017-07-19
RU2013146602A (ru)	2015-04-27
PL2689777T3 (pl)	2018-08-31
EP2689777A2 (en)	2014-01-29
EP2689777B1 (en)	2018-03-28
CN103442709A (zh)	2013-12-11
KR101981378B1 (ko)	2019-05-22
ES2668785T3 (es)	2018-05-22

Legal Events

Date	Code	Title	Description
2012-11-14	121	Ep: the epo has been informed by wipo that ep was designated in this application	Ref document number: 11861553 Country of ref document: EP Kind code of ref document: A2
2013-09-18	ENP	Entry into the national phase	Ref document number: 2830616 Country of ref document: CA
2013-09-20	ENP	Entry into the national phase	Ref document number: 2014500226 Country of ref document: JP Kind code of ref document: A
2013-09-23	NENP	Non-entry into the national phase	Ref country code: DE
2013-09-25	WWE	Wipo information: entry into national phase	Ref document number: 2011861553 Country of ref document: EP
2013-10-21	ENP	Entry into the national phase	Ref document number: 20137027665 Country of ref document: KR Kind code of ref document: A
2013-10-22	ENP	Entry into the national phase	Ref document number: 2013146602 Country of ref document: RU Kind code of ref document: A
2013-10-31	ENP	Entry into the national phase	Ref document number: 2011362905 Country of ref document: AU Date of ref document: 20110322 Kind code of ref document: A

Publication	Publication Date	Title
EA026667B9 (ru)	2017-07-31	Фармацевтическая композиция для лечения вируса гепатита с
JP2016503793A5 (zh)	2017-02-02
HRP20171175T1 (hr)	2017-10-06	Novi triciklički spojevi
WO2008137779A3 (en)	2009-01-08	Novel macrocyclic inhibitors of hepatitis c virus replication
MX2012008658A (es)	2012-12-05	Inhibidores del virus de la hepatitis c.
WO2013059278A3 (en)	2014-05-22	Hepatitis c virus inhibitors
EP2555622A4 (en)	2013-09-18	HEPATITIS C-VIRUS HEMMER
WO2009053828A3 (en)	2009-12-30	P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
NZ724503A (en)	2017-12-22	Macrocyclic inhibitors of flaviviridae viruses
MX2012004032A (es)	2012-05-08	Compuestos para el tratamiento de hepatitis c.
BRPI1013394A2 (pt)	2016-06-21	"composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
WO2008021960A3 (en)	2008-11-06	Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2011127333A3 (en)	2012-02-02	Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2014014765A (es)	2015-04-13	Inhibidores macrociclicos de virus flaviviridae.
WO2008021871A3 (en)	2008-10-23	Triazolyl acyclic hepatitis c serine protease inhibitors
MX2019013037A (es)	2020-02-05	Prolina macrociclica derivada de inhibidores de serina proteasa de vhc.
JP2013510120A5 (zh)	2013-11-07
MX2009009473A (es)	2009-09-15	Compuestos para el tratamiento de hepatitis c.
WO2009076166A3 (en)	2009-12-30	Oximyl hcv serine protease inhibitors
WO2008100867A3 (en)	2009-01-08	Novel inhibitors hepatitis c virus replication
JP2013542247A5 (zh)	2014-12-18
WO2007143694A3 (en)	2008-11-20	Macrocyclic oximyl hepatitis c protease inhibitors
MX2012008211A (es)	2012-08-08	Inhibidores de virus flaviviridae.
WO2011049908A3 (en)	2011-09-22	Bismacrokyclic compounds as hepatitis c virus inhibitors
WO2012126178A3 (zh)	2012-11-22	用于治疗肝脏疾病的药物组合物